- Current report filing (8-K)
10 Août 2009 - 10:04PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
August 10, 2009
ALLOS
THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
|
|
|
|
|
11080
CirclePoint Road, Suite 200
|
|
|
Westminster,
Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8
Other Events
Item
8.01 Other Events.
On August 10, 2009,
Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a
press release announcing that the Company has received notification from the
U.S. Food and Drug Administration that the Oncologic Drugs Advisory Committee
will hold a meeting on September 2, 2009, to review the Companys New Drug
Application for pralatrexate for the treatment of patients
with relapsed or refractory peripheral T-cell lymphoma
. The
press release is attached hereto as Exhibit 99.1 and incorporated herein
by reference.
Section 9
Financial Statements and Exhibits
Item
9.01 Financial Statements
and Exhibits.
(d) Exhibits
99.1
|
|
Press Release, dated
August 10, 2009, entitled Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate
for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell
Lymphoma.
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: August 10, 2009
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President, General
Counsel and Secretary
|
3
EXHIBIT
INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
August 10, 2009, entitled Allos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate
for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell
Lymphoma.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024